Post-Transplant Cyclophosphamide (PTCY) Improves Outcomes Among Allogeneichematopoietic Cell Transplantation (HSCT) Recipients with High Comorbidity Score Compared to Standardgraft-Versus-Host Disease (GVHD) Prophylaxis

Key Points

• Post-transplant cyclophosphamide improves clinical outcomes in patients with high comorbidity.
• Patients receiving this treatment showed a significant decrease in graft-versus-host disease progression.
• This approach utilizes a tailored strategy to manage comorbidities effectively during HSCT.
• Potential implications highlight the need for personalized treatment protocols in HSCT populations.